UK HealthCare logo

Practice areas

  • Hepatobiliary/Pancreatic Cancer Team
  • Liver Cancer Team
  • Pancreas Cancer Team
  • Pediatric Kidney Transplant Team
  • Transplant Surgery
  • Transplant: Additional
  • Transplant: Hepatobiliary
  • Transplant: Kidney
  • Transplant: Kidney/Pancreas
  • Transplant: Liver
  • Transplant: Pancreas

Faculty rank

Professor of Surgery

Clinic information

Clinical interests

  • Abdominal Transplant Surgery
  • General Surgery
  • Liver, Kidney and Pancreas Transplantation



Central University of Venezuela, Razetti School of Medicine, Caracas, Venezuela


University Hospital of Caracas, Central University of Venezuela, Caracas, Venezuela


Deaconess Hospital, Harvard University, Boston
Jackson Memorial Hospital, University of Miami, Fla.
Methodist Hospital, University of Tennessee, Memphis

Certifications or Special training

Member, American Association for the Study of Liver Diseases
Member, American Society of Transplant Surgeons
Member, American Society of Transplant Physicians
Member, International Liver Transplantation Society
Member, Venezuelan Surgical Society
Member, Kentucky Organ Donor Affiliates (KODA) Executive Board of Directors
Member, KODA Advisory Committee
Member, University of Kentucky Organ Transplant Evaluation Committees (liver, pancreas, kidney)

Additional information


Roberto Gedaly is a practicing transplant surgeon and clinician-scientist who has earned both national and international recognition for his work with infectious complications, including hepatitis and patients undergoing liver resection and liver transplantation. His research has focused on immunosuppressive strategies in liver transplantation. His currently seeks to define markers and prognostic indicators of hepatocellular carcinoma in an attempt to determine more effective therapies.

After receiving a medical degree from the Universidad Central de Venezuela in Caracas, Venezuela in 1990, Gedaly completed his general surgery residency at the University Hospital of Caracas. He then completed a two-year fellowship in hepatobiliary and transplantation service at Beth Israel Deaconess Medical Center through the Harvard Medical School in Boston; a one-year fellowship in liver and GI transplantation at the Jackson Memorial Hospital at the University of Miami School of Medicine in Miami, Fla.; and a two-year fellowship in transplantation at the Methodist Hospital at the University of Tennessee in Memphis. Gedaly joined the University of Kentucky in 2006. He is actively engaged in medical and surgical societies, is a frequently invited guest speaker at meetings worldwide and has authored numerous publications appearing in leading peer-review journals and text books.



Roberto Gedaly, Roberto Galuppo, Yolanda Musgrave, Paul Angulo, Jonathan Hundley, Malay Shah, Michael F. Daily, Changguo Chen, Donald A. Cohen, Brett T. Spear and B. Mark Evers. PKI-587 and Sorafenib Alone and in Combination on Inhibition of Liver Cancer Stem Cell Proliferation. J. Surg. Res 2013 E-Pub before Print

Gedaly R, Angulo P, Chen C, Creasy KT, Spear BT, Hundley J, et al. The Role of PI3K/mTOR Inhibition in Combination with Sorafenib in Hepatocellular Carcinoma Treatment. Anticancer Res 32:2531-2536, 2012

Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, Evers BM. PKI-587 and Sorafenib Targeting PI3K/AKT/mTOR and Ras/Raf/MAPK Pathways Synergistically Inhibit HCC Cell Proliferation. J Surg Res 176: 542-548, 2012

Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, Koch A, and Evers BM: PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. Anticancer Res 30:4951-4958, 2010

Gedaly R, McHugh PP, Johnston TD, Jeon H, Koch A, Clifford TM, Ranjan D. Predictors of relapse to alcohol and illicit drugs after liver transplantation for alcoholic liver disease. Transplantation 86(8):1090-1095, 2008